201 related articles for article (PubMed ID: 26126915)
1. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
Dal Corso A; Pignataro L; Belvisi L; Gennari C
Curr Top Med Chem; 2016; 16(3):314-29. PubMed ID: 26126915
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
3. Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide.
Feni L; Parente S; Robert C; Gazzola S; Arosio D; Piarulli U; Neundorf I
Bioconjug Chem; 2019 Jul; 30(7):2011-2022. PubMed ID: 31243977
[TBL] [Abstract][Full Text] [Related]
4. alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers.
Rerat V; Dive G; Cordi AA; Tucker GC; Bareille R; Amédée J; Bordenave L; Marchand-Brynaert J
J Med Chem; 2009 Nov; 52(22):7029-43. PubMed ID: 19860432
[TBL] [Abstract][Full Text] [Related]
5. Multimeric Presentation of RGD Peptidomimetics Enhances Integrin Binding and Tumor Cell Uptake.
Pina A; Kadri M; Arosio D; Dal Corso A; Coll JL; Gennari C; Boturyn D
Chemistry; 2020 Jun; 26(33):7492-7496. PubMed ID: 32227540
[TBL] [Abstract][Full Text] [Related]
6. Design of integrin α
Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
[TBL] [Abstract][Full Text] [Related]
7. Biological Relevance of RGD-Integrin Subtype-Specific Ligands in Cancer.
Sani S; Messe M; Fuchs Q; Pierrevelcin M; Laquerriere P; Entz-Werle N; Reita D; Etienne-Selloum N; Bruban V; Choulier L; Martin S; Dontenwill M
Chembiochem; 2021 Apr; 22(7):1151-1160. PubMed ID: 33140906
[TBL] [Abstract][Full Text] [Related]
8. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
9. RGD mimetics γ-AApeptides and methods of use (US 20,140,004,039 A1): a patent evaluation.
Wu H; Jiang J; Xu H; Li Q; Cai J
Expert Opin Ther Pat; 2016; 26(1):131-7. PubMed ID: 26560186
[TBL] [Abstract][Full Text] [Related]
10. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.
Temming K; Schiffelers RM; Molema G; Kok RJ
Drug Resist Updat; 2005 Dec; 8(6):381-402. PubMed ID: 16309948
[TBL] [Abstract][Full Text] [Related]
11. RGD Peptidomimetic MMAE-Conjugate Addressing Integrin αVβ3-Expressing Cells with High Targeting Index.
Paulus J; Nachtigall B; Meyer P; Sewald N
Chemistry; 2023 Feb; 29(12):e202203476. PubMed ID: 36454662
[TBL] [Abstract][Full Text] [Related]
12. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
13. αvβ3- or α5β1-Integrin-Selective Peptidomimetics for Surface Coating.
Mas-Moruno C; Fraioli R; Rechenmacher F; Neubauer S; Kapp TG; Kessler H
Angew Chem Int Ed Engl; 2016 Jun; 55(25):7048-67. PubMed ID: 27258759
[TBL] [Abstract][Full Text] [Related]
14. Cyclic RGD and
Panzeri S; Arosio D; Gazzola S; Belvisi L; Civera M; Potenza D; Vasile F; Kemker I; Ertl T; Sewald N; Reiser O; Piarulli U
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339382
[TBL] [Abstract][Full Text] [Related]
15. Cyclopropane pipecolic acids as templates for linear and cyclic peptidomimetics: application in the synthesis of an Arg-Gly-Asp (RGD)-containing peptide as an αvβ3 integrin ligand.
Sernissi L; Petrović M; Scarpi D; Guarna A; Trabocchi A; Bianchini F; Occhiato EG
Chemistry; 2014 Aug; 20(35):11187-203. PubMed ID: 25069617
[TBL] [Abstract][Full Text] [Related]
16. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
17. Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin α
Raposo Moreira Dias A; Pina A; Dal Corso A; Arosio D; Belvisi L; Pignataro L; Caruso M; Gennari C
Chemistry; 2017 Oct; 23(58):14410-14415. PubMed ID: 28816404
[TBL] [Abstract][Full Text] [Related]
18. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment.
Paulus J; Sewald N
J Pept Sci; 2024 Jul; 30(7):e3561. PubMed ID: 38382900
[TBL] [Abstract][Full Text] [Related]
19. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
20. Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy.
Dal Pozzo A; Esposito E; Ni M; Muzi L; Pisano C; Bucci F; Vesci L; Castorina M; Penco S
Bioconjug Chem; 2010 Nov; 21(11):1956-67. PubMed ID: 20949910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
